News and Events

I-ACT for Children Commentary Published in Pediatric Infectious Disease Journal

Sept. 1, 2020 – The FDA’s inclusion of children in its Emergency Use Authorization for use of remdesivir in treating serious COVID-19 disease is an important milestone, as it provides children with access to the medication at the same level of urgency afforded adults, according to an I-ACT for Children commentary published this week in…

I-ACT for Children’s Collin Hovinga, PharmD, Named to FDA Advisory Panel

Collin Hovinga, PharmD, has been named to a four-year term as a member of the U.S. Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. Dr. Hovinga, SVP of Clinical and Scientific Development at I-ACT for Children, joined the organization in 2018 and plays a lead role on many of our proprietary and…

Virtual Workshop Addresses Development of Pediatric Treatments for COVID-19

I-ACT for Children held a virtual workshop – “Developing Pediatric Treatments for COVID-19” – to discuss the progress of (and challenges related to) developing pediatric COVID-19 treatments with regulators, biopharma developers and experts on the front lines of treating children with COVID-19. Speakers shared the latest on the clinical presentation of COVID-19 in children, the…

New article in Pediatric Research provides roadmap for critically needed COVID-19 research in children

FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com   Article by I-ACT for Children, other leading pediatric researchers stresses urgency in addressing the questions surrounding children and the disease   Rockville, MD– Increasing reports of severe COVID-19 illness in children – coupled with the fact that little is known about how and why…

I-ACT for Children Launches Emergency Access Program to Speed Pediatric Clinical Trials for COVID-19

FOR IMMEDIATE RELEASE Contact: Berna Diehl Phone: 202-725-2553 Email: berna@brightoncomms.com Emergency program will allow any company developing COVID-19 treatments or vaccines to tap into pediatric global network, trial-planning experts Rockville, MD, – As the number of children with severe COVID-19 illness grows, there is increasing urgency to ensure that potential treatments and vaccines are tested for…

I-ACT for Children Welcomes Gary Noel, MD, as Chief Medical Officer

The Institute for Advanced Clinical Trials (I-ACT) for Children is pleased to announce the appointment of Gary Noel, MD, as its Chief Medical Officer. Dr. Noel is a pediatrician, child advocate, specialist in Infectious Diseases and Immunology and a seasoned expert in drug development, having spent more than 30 years in leadership roles in the…

2019 – SOCRA Annual Conference

For the 28th year, SOCRA will welcome clinical research professionals from across the world. Located in San Antonio, TX at the Grand Hyatt San Antonio, this three day conference will offer current information and tools, best practices, and training to assure that you’re up-to-date and compliant in your clinical research practice. The program will feature…

The Duchenne Platform Trial Stakeholder Meeting

The Duchenne Platform Trial is being designed to increase access to therapeutic trials across the Duchenne community, with the goals of: More rapid completion of testing and approval of new DMD therapies Reduced clinical trial start-up and execution time Enhanced patient experience, reduced number on placebo Potential for rapidly testing combination therapies The trial will…

I-ACT FOR CHILDREN TO CO-HOST DUCHENNE MUSCULAR DYSTROPHY PLATFORM TRIAL STAKEHOLDER MEETING

SHERATON SILVER SPRING | SILVER SPRING, MD SEPTEMBER 9, 2019 | 8:30 AM-4:30 PM I-ACT for Children will co-host the first Duchenne Muscular Dystrophy Platform Trial Community Meeting on Sept. 9 with collaborators Parent Project Muscular Dystrophy and the Critical Path Institute. The Duchenne Platform Trial is being designed to increase access to therapeutic trials…

I-ACT for Children Selects Advarra as Central IRB for its Pediatric Clinical Trials Site Network

I-ACT for Children has selected Advarra as the central IRB for the I-ACT for Children Clinical Trials Site Network – a geographically and therapeutically diverse network of pediatric trial sites committed to improving efficiencies and capabilities for the conduct of clinical trials. I-ACT for Children launched the central IRB function to streamline processes, expedite IRB…